Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Autolus Therapeutics plc - American Depositary Shares (NQ:AUTL)

2.300 -0.100 (-4.17%)
Streaming Delayed Price Updated: 2:58 PM EDT, Aug 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Autolus Therapeutics plc - American Depositary Shares

< Previous 1 2 3 4 Next >
FDA Eases Access To Life-Saving Gene Therapies For Blood Cancers
FDA lifts REMS for approved CAR-T therapies, easing hospital restrictions and signaling broader future access in oncology and autoimmune treatment. 
Via Benzinga
What 4 Analyst Ratings Have To Say About Autolus Therapeutics
 
Via Benzinga
Autolus Therapeutics Gets Favorable Recommendation For Approval Of Cancer Therapy In EU: Retail Sentiment Brightens
CHMP has recommended that the European Commission approve the therapy for treating adult patients over the age of 26 with relapsed or refractory B-cell precursor acute Lymphoblastic Leukemia. 
Via Stocktwits
Topics Artificial Intelligence
Earnings Scheduled For May 8, 2025
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
Earnings Scheduled For November 12, 2024
 
Via Benzinga
A Glimpse Into The Expert Outlook On Autolus Therapeutics Through 5 Analysts
 
Via Benzinga
Breaking Down Autolus Therapeutics: 4 Analysts Share Their Views
 
Via Benzinga
Earnings Scheduled For March 20, 2025
 
Via Benzinga
This InterContinental Hotels Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday
 
Via Benzinga
Autolus Therapeutics's Earnings Outlook
 
Via Benzinga
Analyst Expectations for Autolus Therapeutics's Future
 
Via Benzinga
Nvidia To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Tuesday
 
Via Benzinga
Why Revelation Biosciences Shares Are Trading Higher By Around 49%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
AUTL Stock Earnings: Autolus Therapeutics Misses EPS for Q2 2024
AUTL stock results show that Autolus Therapeutics missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Stocks to Buy: 3 Biotech Bargains Delivering Breakthroughs on a Budget
Since wealth without health is utterly meaningless, investors may have some confidence with these biotech stocks to buy. 
Via InvestorPlace
Crude Oil Gains 1%; GameStop Shares Plunge
 
Via Benzinga
Why Cracker Barrel Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Friday's Mid-Day Session
 
Via Benzinga
AUTL Stock Earnings: Autolus Therapeutics Misses EPS, Misses Revenue for Q1 2024
AUTL stock results show that Autolus Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Despegar.com Posts Strong Sales, Joins Reddit, Robinhood And Other Big Stocks Moving Higher On Friday
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
 
Via Benzinga
Earnings Scheduled For March 14, 2024
Companies Reporting Before The Bell • Pharming (NASDAQ:PHAR) is projected to report earnings for its fourth quarter. 
Via Benzinga
Chart Of The Day: Autolus Therapeutics - Effective Cancer Treatments
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. 
Via Talk Markets
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
Autolus Therapeutics' Obe-Cel's Shows Compelling Safety Over Gilead's Drug For Acute Lymphoblastic Leukemia
Truist has raised the price target for Autolus Therapeutics PLC (NASDAQ: AUTL) from $6 to $9  
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.